series-a
Stage
About
ErVimmune is a French biotechnology company developing cancer vaccines and T cell-based therapies that target shared non-conventional tumor antigens derived from human endogenous retroviruses to treat cold tumors with unmet medical needs. It uses a proprietary AI-driven target discovery platform validated by proteomics and immunology assays.
Explore ErVimmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.